Il-4r and tslp inhibitors and methods of use thereof

An antibody comprising:

• (a) an anti-IL-4R moiety or an antigen binding portion thereof,
• wherein the anti-IL-4R moiety or the antigen binding portion thereof comprises a light chain (LIL-4R) and a heavy chain (HIL-4R);
• wherein the LIL-4R comprises alight chain variable domain, wherein the light chain variable domain comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:
• 30;
• and
• wherein the HIL-4R comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:
• 32;
• and
• (b) an anti-thymic stromal lymphopoietin (TSLP) moiety or an antigen binding portion thereof comprising a Fab,
• wherein the Fab comprises a first peptide chain comprising a heavy chain variable domain (VHTSLP) and a heavy chain constant domain 1 (CH1TSLP), and a second peptide chain comprising a light chain variable domain (VLTSLP), and a light chain constant domain (CLTSLP);
• wherein the VHTSLP comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
• 25;
• and
• wherein the VLTSLP comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
• 28,
• wherein the anti-IL-4R moiety or the antigen binding portion thereof comprises a Fc region comprising one or more mutations, wherein the one or more mutations comprise a half-life extension modification, effector silencing, or prevention of Fab arm exchange of IgG;
• and wherein the second peptide chain is associated with at least a portion of the Fc region.